Comparison of Senza to Commercial Spinal Cord Stimulation for the Treatment of Chronic Pain
Unknown statusNot applicableNCT01609972
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this investigational study is to establish the safety and effectiveness of electrical stimulation delivered to the spinal cord in subjects with chronic, intractable pain of the trunk and/or limbs and will be a comparison of the Senza System with commercially available SCS systems.
Study details
- Official title
- Multi-Center, Prospective, Randomized, Controlled Clinical Trial to Demonstrate Non-Inferiority of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Pain as Compared to Commercially Available SCS Devices
- Conditions
- Interventions
- Sponsor
- Nevro Corp
- Start date
- 2012-06
- Primary completion
- 2015-05
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Have been diagnosed with chronic, intractable pain of the trunk and/or limbs (VAS ≥ 5) which has been refractory to conservative therapy for a minimum of 3 months. * Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician * Be 18 years of age or older at the time of enrollment * Be willing and capable of giving informed consent * Be willing and able to comply with study-related requirements, procedures, and visits Exclusion Criteria: * Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator * Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by a psychologist * Have a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus * Have a diagnosis of scoliosis that precludes lead placement * Have an existing drug pump and/or SCS system or another active implantable device such as a pacemaker * Have prior experience with SCS * Have a condition currently requiring or likely to require the use of MRI or diathermy * Have metastatic malignant disease or active local malignant disease * Have a life expectancy of less than 1 year * Have an active systemic or local infection * Be pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal) * Have within 6 months of enrollment a significant untreated addiction to dependency producing medications or have been a substance abuser (including alcohol and illicit drugs) * Be concomitantly participating in another clinical study * Be involved in an injury claim under current litigation * Have a pending or approved worker's compensation claim
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01609972